These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15679862)

  • 1. The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas.
    Maes L; Lippens E; Kalala JP; de Ridder L
    Cell Prolif; 2005 Feb; 38(1):3-12. PubMed ID: 15679862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCNA, Ki-67 and hTERT in residual benign meningiomas.
    Maes L; Kalala JP; Cornelissen M; De Ridder L
    In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of astrocytomas and meningiomas: an evaluation in vitro.
    Maes L; Kalala JP; Cornelissen M; de Ridder L
    Cell Prolif; 2007 Feb; 40(1):14-23. PubMed ID: 17227292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
    Roser F; Samii M; Ostertag H; Bellinzona M
    Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
    Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
    Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
    Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas.
    Konstantinidou AE; Patsouris E; Korkolopoulou P; Kavantzas N; Mahera H; Davaris P
    Histopathology; 2001 Oct; 39(4):402-8. PubMed ID: 11683942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hTERT protein as a marker for malignancy in meningiomas.
    Kalala JP; Maes L; Vandenbroecke C; de Ridder L
    Oncol Rep; 2005 Feb; 13(2):273-7. PubMed ID: 15643510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time.
    Kakinuma K; Tanaka R; Onda K; Takahashi H
    Acta Neurochir (Wien); 1998; 140(1):26-31; discussion 31-2. PubMed ID: 9522904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
    Ozen O; Demirhan B; Altinörs N
    Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
    Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
    APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
    Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I
    J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
    Korshunov A; Shishkina L; Golanov A
    Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
    Karamitopoulou E; Perentes E; Tolnay M; Probst A
    Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningiomas.
    Mukherjee S; Ghosh SN; Chatterjee U; Chatterjee S
    Neurol India; 2011; 59(6):817-22. PubMed ID: 22234191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase activity and hTERT protein expression in meningiomas: an analysis in vivo versus in vitro.
    Maes L; Kalala JP; Cornelissen R; de Ridder L
    Anticancer Res; 2006; 26(3B):2295-300. PubMed ID: 16821605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas.
    Konstantinidou AE; Korkolopoulou P; Kavantzas N; Mahera H; Thymara I; Kotsiakis X; Perdiki M; Patsouris E; Davaris P
    Histol Histopathol; 2003 Jan; 18(1):67-74. PubMed ID: 12507285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
    Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.